NLRP3 and diabetes mellitus: Since pharmacological targeting of the NLRP3 inflammasome alleviates pancreatic inflammation and β-cell death in preclinical models [50–53], small molecules targeting IRE1α RNase activity and/or the NLRP3 inflammasome could be attractive strategies in diabetes and chronic metabolic diseases.